Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMOSQGU)

Drug Name

Nalbuphine Drug Info

Synonyms

Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1]
Prurigo nodularis	EC91.0	Phase 2/3	[2]
Uremic pruritus	EC90.10	Phase 2/3	[2]

Therapeutic Class

Analgesics

Cross-matching ID

PubChem CID: 5311304
ChEBI ID: CHEBI:7454
CAS Number: CAS 20594-83-6
TTD Drug ID: DMOSQGU
VARIDT Drug ID: DR01344

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor kappa (OPRK1)	TTQW87Y	OPRK_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	Highest Status	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Approved	[4]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Opioid receptor kappa (OPRK1)	DTT	OPRK1	5.533	5.372	5.703	5.632
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.009	6.988	7.442	8.135

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Pain

ICD Disease Classification

MG30-MG3Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor kappa (OPRK1)	DTT	OPRK1	9.17E-01	0.04	0.1
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.26E-01	-3.59E-03	-1.34E-02

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1663).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.